Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Protamine Dosing for Heparin Reversal
NCT05426031Phase 4Completed
- Sponsor
- University of Miami
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of protamine (2 arms), sponsored by University of Miami. Primary endpoint: Activated Clotting Time. Started Jun 2022; status: completed.
02
Drugs
protamine
Beyond the preview
Go deeper on NCT05426031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426031.